Acute Mesenteric Ischemia

Acute mesenteric ischemia (AMI) is a life-threatening vascular emergency initiated by abrupt interruption of intestinal blood flow, most often from arterial occlusion, mesenteric venous thrombosis, or non-occlusive hypoperfusion.

Also Called / Synonyms

• Acute intestinal ischemia, mesenteric infarction, acute splanchnic ischemia
• Subtype-specific synonyms: superior mesenteric artery (SMA) embolus, SMA thrombus, mesenteric venous thrombosis (MVT), non-occlusive mesenteric ischemia (NOMI)

Etiologic Classification

The clinical course and management of AMI depend critically on the underlying mechanism. The four classic etiologic subtypes are listed below; a fifth category includes secondary ischemia from mechanical causes such as strangulating obstruction or aortic dissection.

*Percentages from a single-center retrospective cohort ^[6]B2b; arterial occlusive AMI is the most common subtype overall.

Clinical Significance

AMI is a rare but catastrophic event. A population-based study from Estonia reported an annual incidence of 8.7 per 100,000 with a median age of 79 years and 57% female ^[2]B2b. Overall hospital mortality was 64%, though among the 53% of patients who received active treatment it fell to 32%; 1-year all-cause mortality in the treated group was 51% ^[2]B2b. In a separate Italian cohort, in-hospital mortality was 41.2% and 30-day mortality 46.5% ^[6]B2b. The urgency of recognition and the specific management pathway (endovascular versus open revascularization, anticoagulation, or supportive care) are dictated by the subtype, making early classification a life-saving step.

Pearl: The single most important triage decision in AMI is identifying the etiologic subtype, because an embolus requires embolectomy, a thrombus may need bypass or stenting, venous ischemia is treated with anticoagulation, and NOMI demands reversal of the underlying shock state, applying the wrong algorithm to the wrong subtype worsens outcome.

The next section details the pathophysiology and surgical lesion that distinguishes each subtype.

From the classification of subtypes, the pathophysiologic cascade that follows each insult determines the clinical trajectory and the surgical target. The small intestine can compensate for a 75% reduction in mesenteric blood flow for up to 12 hours through collateral circulation and autoregulatory vasodilation ^[10]A1c. Beyond this window, cellular hypoxia overwhelms compensatory mechanisms and irreversible injury begins.

The Ischemic Cascade

The sequence from occlusion to necrosis proceeds through discrete, time-dependent steps:

1. Reduced perfusion, Arterial occlusion (embolic or thrombotic), venous outflow obstruction, or splanchnic vasoconstriction (NOMI) decreases oxygen delivery below the critical threshold.
2. Mucosal hypoxia, The villi, most metabolically active, suffer first. Loss of the mucosal barrier permits bacterial translocation and triggers a local inflammatory response.
3. Transmural progression, Continued ischemia extends from mucosa through submucosa and muscularis propria. Once the serosa is involved, transmural necrosis is established.
4. Perforation and peritonitis, Full-thickness necrosis leads to bowel perforation, fecal contamination, and septic shock.

Subtype-Specific Pathoanatomy

The location and mechanism of vascular compromise dictate the pattern of bowel involvement:

• SMA embolism, The majority of emboli lodge 3-10 cm distal to the SMA origin, classically sparing the proximal jejunum and colon ^[10]A1c. More than 20% of SMA emboli are associated with concurrent emboli to another arterial bed, such as the spleen or kidney ^[9]A1c.
• SMA thrombosis, Typically occurs at the origin of the SMA on a background of atherosclerotic plaque. The entire small bowel and right colon are at risk because the occlusion is proximal to major collateral pathways.
• Mesenteric venous thrombosis, Outflow obstruction produces hemorrhagic infarction with bowel wall thickening and edema. The onset is often subacute, and the ischemic segment may be longer than in arterial occlusion.
• Non-occlusive mesenteric ischemia (NOMI), Splanchnic vasoconstriction from low-flow states (e.g., cardiogenic shock , vasopressors) causes patchy, often segmental ischemia, most pronounced in the watershed areas of the splenic flexure and rectosigmoid.

The Surgical Lesion: Transmural Necrosis

Transmural necrosis is the point of no return, bowel that has progressed to full-thickness infarction cannot recover and must be resected. Clinical signs of peritonitis, metabolic acidosis, and organ failure indicate established transmural necrosis. Radiologic predictors include bowel wall thinning (DOR 13.10), decreased or absent bowel wall enhancement (DOR 5.77), pneumatosis intestinalis (DOR 5.78), and porto-mesenteric venous gas (DOR 5.36) ^[13]B2a. Independent clinical predictors are mesenteric arterial occlusion (OR 26.5), leukocytosis, acidosis, free intraperitoneal fluid, and combined portal vein-SMV thrombosis ^[17]B2b.

A plasma biomarker, SM22, rises significantly from 4 hours of ischemia onward in animal models, reflecting smooth muscle injury and transmural involvement ^[11]B3b.

Reperfusion Injury and Systemic Sequelae

Restoring blood flow, whether by embolectomy, bypass, or endovascular intervention, paradoxically amplifies tissue damage. Reperfusion triggers a burst of oxygen free radicals, complement activation, and neutrophil infiltration that can convert viable but stunned bowel into necrotic tissue. This systemic inflammatory response contributes to acute lung injury in nearly 30% of patients and is a major driver of mortality ^[23]D5.

Pearl: The 12-hour window of compensation means that any delay in diagnosis beyond this threshold dramatically increases the likelihood of transmural necrosis; a patient with peritonitis and acidosis likely has irreversible bowel injury and requires immediate resection, not prolonged imaging.

From the pathophysiologic substrate of inadequate mesenteric perfusion, the clinical burden of acute mesenteric ischemia emerges with an incidence of 8.7 per 100,000 in population-based studies ^[2]B2b. The median age at presentation is 79 years (range 32-104), with a female predominance (57%) ^[2]B2b. Overall hospital mortality remains 64%, and 1‑year all-cause mortality 74%; among patients who receive active treatment, hospital mortality falls to 32% and 1‑year mortality to 51% ^[2]B2b.

Etiologic Subtypes

Roughly 50% of all cases are due to acute mesenteric embolism ^[10]A1c. More than 20% of SMA emboli are associated with concurrent emboli to another arterial bed, including the spleen and kidney ^[9]A1c. SMA thrombosis typically arises on pre-existing atherosclerotic stenosis, while mesenteric venous thrombosis and non-occlusive mesenteric ischemia (NOMI) account for the remainder. NOMI has been reported as a rare extrapulmonary complication of Mycoplasma pneumoniae infection in children ^[32]C4.

Risk Factors

Several modifiable and non-modifiable factors increase the risk of AMI and its progression to transmural necrosis. The strongest modifiable risk factors are current smoking (aHR 3.02) and high alcohol consumption (aHR 2.53), while high physical activity (25.1-50.0 MET-h/week) is protective (aHR 0.51) ^[33]B2b. Morbid obesity with hypertension , hyperlipidemia, or diabetes also confers high risk ^[19]C4.

Non-modifiable risk factors include advanced age (median 79 years ^[2]B2b), pre-existing cardiac disease ^[28]B2b, and the presence of arterial thrombosis (compared to embolism, thrombosis carries higher risk of AMI recurrence: HR 5.97) ^[34]B2b.

Pearl: The strongest modifiable risk factors for AMI are current smoking (3-fold increased risk) and high alcohol consumption (2.5-fold), while high physical activity reduces risk by half, these are actionable targets for prevention ^[33]B2b.

From the preceding epidemiology , it is clear that patients with acute mesenteric ischemia (AMI) often harbor risk factors such as atrial fibrillation , atherosclerotic disease, or hypercoagulable states, but the clinical presentation is the first critical filter. The classic dictum, pain out of proportion to physical examination, remains the most sensitive early clue, yet it is neither universal nor pathognomonic.

Presenting Symptoms

The onset and character of pain vary by etiologic subtype. SMA embolism typically presents with sudden, severe, periumbilical pain that rapidly escalates, often accompanied by vomiting or forceful bowel evacuation. The small intestine can compensate for up to a 75% reduction in blood flow for 12 hours ^[10]A1c, but once the ischemic threshold is crossed, the patient’s pain becomes relentless. Emboli lodge 3-10 cm distal to the SMA origin, classically sparing the proximal jejunum and colon ^[10]A1c. In 20% of SMA emboli, concurrent emboli to another arterial bed (spleen, kidney) are present and should be sought ^[9]A1c.

• SMA thrombosis often follows a more insidious course, with a prodrome of postprandial abdominal pain ( chronic mesenteric ischemia ) that then becomes constant and severe as acute occlusion occurs.
• Mesenteric venous thrombosis presents with subacute, diffuse abdominal pain, nausea, and diarrhea that may evolve over days.
• Non-occlusive mesenteric ischemia (NOMI) occurs in critically ill patients on vasopressors or with low-flow states; pain may be masked by sedation or altered mental status.

Other symptoms include nausea, vomiting, diarrhea (often bloody), and, in late stages, obstipation from ileus. The timeline is critical: an inflection point at 48 hours from symptom onset has been identified (sensitivity 81%, specificity 63%), beyond which perioperative mortality rises from 14% to 39% and short bowel syndrome from 12% to 39% ^[34]B2b.

Autonomic and Vital Signs

Early in the course, vital signs may be normal or show only tachycardia. As bowel ischemia progresses, autonomic instability ensues: hypotension, tachypnea, and oliguria signal incipient shock. The abdominal examination may initially reveal only mild tenderness with no guarding or rebound. However, the presence of peritoneal signs (rigidity, rebound, involuntary guarding) indicates transmural necrosis and mandates urgent laparotomy. Independent predictors of transmural bowel necrosis include mesenteric arterial occlusion (OR 26.5), leukocytosis (OR 1.3 per unit), acidosis (OR 3.8), free intraperitoneal fluid (OR 4.21), and combined portal vein and SMV thrombosis on CT ^[17]B2b. Rectal examination often reveals occult blood.

Phenotypic Variants

Red Flags

• Peritoneal signs (rigidity, rebound, guarding) → urgent laparotomy
• Hypotension or need for vasopressors → shock from transmural necrosis
• Oliguria or acute kidney injury → indicating end-organ hypoperfusion
• Age >70 years with metabolic acidosis → increased mortality ^[16]B2b
• Time from symptom onset >48 hours → significantly worse outcomes ^[34]B2b

Atypical Presentations

AMI may be missed in several populations. In NOMI, the patient may be intubated or sedated in the ICU and express pain only as tachycardia or increased ventilator requirements. Bedside laparoscopy has been used in this setting to avoid non-therapeutic laparotomy ^[37]B2b. Post-bariatric surgery patients (especially after sleeve gastrectomy ) with morbid obesity and hypertension , hyperlipidemia, or diabetes are at high risk for mesenteric vein thrombosis ^[19]C4. Children with AMI present a diagnostic challenge because of nonspecific symptoms and low suspicion ^[31]C4. Finally, pneumatosis intestinalis and portal venous gas on CT, once believed to mandate immediate surgery, now require integration with the full clinical picture: overall mortality in modern series is 31%, but in patients with confirmed ischemia it rises to 69% ^[42]B2a.

Pearl: The most reliable early clue is pain out of proportion to the abdominal exam; its absence does not rule out ischemia, but its presence, especially with a thromboembolic risk factor, should trigger immediate CT angiography, the 48-hour window for revascularization is the single most modifiable determinant of outcome.

The clinical features described above, sudden-onset, morphine -requiring abdominal pain, should immediately raise suspicion for acute mesenteric ischemia (AMI), but the diagnosis is confirmed by contrast-enhanced CT angiography (CTA). The imaging and laboratory workup must proceed emergently, because time from symptom onset to revascularization is the dominant modifiable determinant of outcome: an inflection point at 48 hours has been identified, where patients treated beyond that threshold have perioperative mortality of 39% vs 14% and a nearly threefold increase in long-term mortality (HR 2.95) ^[34]B2b.

Gold-Standard Test: Contrast-Enhanced CT Angiography

CTA with dual-phase acquisition (arterial and venous) is the gold standard diagnostic test for AMI ^{[9]A1c [46]D5}. The examination should include non-contrast, arterial (25-30 second delay), and portal venous (60-70 second delay) phases. The arterial phase identifies vascular occlusion, embolus or thrombus, while the venous phase evaluates bowel wall enhancement, mesenteric vein patency, and secondary signs of ischemia. Reported sensitivity for detecting occlusive AMI exceeds 90%, with specificity approaching 95% ^[9]A1c. In patients with renal impairment, the risk of contrast-induced nephropathy must be weighed against the near-certain mortality of a missed diagnosis; prophylactic hydration and low-iodine protocols are recommended, but CTA should not be delayed.

Laboratory Studies

No single biomarker is diagnostic for AMI, but several laboratory abnormalities increase pre-test probability and support the need for urgent CTA. The table below summarizes the most helpful tests.

A negative D-dimer makes AMI unlikely and can help avoid unnecessary CTA, but a positive result is not specific and must be interpreted in context ^[39]B2b. Lactate >2 mmol/L is a late finding and should not be used to exclude the diagnosis; normal lactate does not rule out early AMI. Novel biomarkers such as hypoxia-inducible factor 1α (HIF-1α) and adrenomedullin have shown promise in experimental models, but are not yet validated for clinical use ^[44]D5.

Imaging Findings

Key CTA findings vary by AMI subtype and must be systematically assessed:

• Vascular findings: Arterial occlusion (embolus or thrombus), venous thrombus, lack of bowel wall enhancement, mesenteric stranding, pneumatosis intestinalis, portal venous gas.
• Bowel findings: Wall thickening (early ischemia) or wall thinning (late necrosis), abnormal enhancement (hyperenhancement in reperfusion, hypoenhancement in necrosis), paralytic dilatation.
• Extraintestinal findings: Free intraperitoneal fluid, pneumoperitoneum (if perforation), mesenteric fat stranding.

Pneumatosis intestinalis and portal venous gas have historically been associated with 70% mortality, but contemporary series report an overall mortality of 31% for patients with these findings; among those with confirmed ischemia, mortality rises to 69% ^[42]B2a. Thus, the decision for surgery should not be based solely on these signs but rather on the full clinical picture ^[42]B2a. The meta-analysis by Reintam Blaser et al. confirms that no single non-vascular feature is sufficiently reliable to diagnose AMI or its progression to transmural necrosis; a combination of radiological features yields the best predictive value ^[41]A1a.

Diagnostic Algorithm

Step 1: Any patient with sudden-onset, morphine-requiring abdominal pain, especially with risk factors (age >65, atrial fibrillation , hypercoagulable state, prior cardiovascular disease) should undergo immediate laboratory evaluation and CTA ^{[9]A1c [12]B3b}. Step 2: If CTA shows arterial or venous occlusion, or clear signs of bowel ischemia, the diagnosis of AMI is established. Step 3: If CTA is equivocal or negative but clinical suspicion remains high, repeat imaging or early surgical exploration should be performed, delaying beyond 48 hours from symptom onset dramatically worsens outcomes ^[34]B2b.

Differential Diagnosis

The differential for severe acute abdominal pain includes:

• Perforated peptic ulcer (free air on plain film or CT)
• Acute pancreatitis (elevated lipase, peripancreatic fat stranding)
• Diverticulitis (left lower quadrant pain, colonic wall thickening)
• Bowel obstruction (dilated loops, transition point, air-fluid levels)
• Ruptured abdominal aortic aneurysm (pulsatile mass, retroperitoneal hematoma)
• Ovarian torsion (pelvic mass, adnexal tenderness)

Pearl: The single most important diagnostic step is early CTA with dual-phase protocol; a negative CTA effectively rules out occlusive AMI in the setting of clinical suspicion. However, non-occlusive mesenteric ischemia (NOMI) may be subtle on CTA, and if the clinical picture is compelling, repeat imaging or surgical exploration is warranted.

With the diagnostic workup complete, the next task is to quantify the severity of ischemia and the risk of bowel necrosis, a step that converts the clinical picture into a numeric trigger for operation and predicts perioperative mortality. Several validated scores and indices have been developed for this purpose, each with distinct strengths and limitations.

Prediction Rules for Mortality

The most extensively studied bedside tool is the Haga prediction rule, derived from a cohort of AMI patients with a 51% overall in-hospital mortality ^[57]C4. Two risk scores, R (continuous) and S (integer), are based on two independent prognostic factors: an electrocardiogram scale (odds ratio 1.7, 95%) and the shock index (heart rate / systolic blood pressure; odds ratio 11, 95% CI 1.5-80). The discriminatory ability is good, with an area under the receiver-operating characteristic curve of 0.83 for R and 0.82 for S ^[57]C4.

Data from Haga et al., Digestion 2009 ^[57]C4.

These rules can be applied at any hospital and may assist in medical decision-making, informed consent, and quality-of-care review ^[57]C4.

Operative-Risk Indices and Triage Tools

For patients with nontraumatic abdominal emergencies including AMI, the damage control surgery (DCS) criteria identified age and INR ≥ 1.7 as independent predictors of mortality on multivariate analysis (p = 0.018 and p = 0.001, respectively) ^[16]B2b. Mortality increased stepwise with the number of DCS criteria present: 24% with one criterion, 48% with two, and 62% with three or more ^[16]B2b.

In the specific setting of acute aortic dissection, a deep learning model integrating clinical and imaging data was developed to predict mesenteric malperfusion. In external validation, the integrated model achieved an area under the curve of 0.780, significantly outperforming the benchmark model (0.586) and the MAM model (0.732) ^[8]B2b. The model’s risk score was independently associated with in-hospital mortality (odds ratio 1.030, 95%) ^[8]B2b. Additional metrics: accuracy 0.760, sensitivity 0.667, specificity 0.783, Brier score 0.143 ^[8]B2b.

Biomarkers as Prognostic Adjuncts

Several biomarkers have been evaluated for their ability to predict severity or bowel necrosis. In a systematic review of 20 studies (2043 participants), D-dimer had the highest median sensitivity for AMI at 93%, while lactate and neutrophil-to-lymphocyte ratio (NLR) had median specificities of 85.9% and 85.8%, respectively ^[49]B2a. Elevated red cell distribution width (RDW), mean platelet volume (MPV), and white blood cell count are associated with AMI diagnosis ^[39]B2b and may carry prognostic value in gastrointestinal disorders ^[54]D5. The plasma biomarker SM22 rises significantly in rats from 4 hours of ischemia onward, suggesting potential for early detection of transmural injury ^[11]B3b. However, none of these biomarkers have been validated in prospective risk stratification trials, and their role remains adjunctive to clinical scores ^[50]A1a.

Pearl: The Haga prediction rule can be calculated at the bedside using only the ECG and shock index, providing a rapid estimate of mortality risk (19% to 91%) that can guide the urgency of operative intervention and the candidness of informed consent ^[57]C4.

From the severity assessment and risk stratification just completed, the clinician transitions immediately to a time-critical resuscitation pathway that parallels the diagnostic workup. The WSES guidelines emphasize that prompt diagnostic and intervention are essential to reduce the high mortality rates (50 to 80%) ^[10]A1c. The small intestine can compensate for a 75% reduction in blood flow for up to 12 hours, but after that, irreversible ischemia progresses rapidly ^[10]A1c. Management proceeds in five coordinated steps, beginning the moment AMI is suspected.

Step 1: Initial Resuscitation and Hemodynamic Support

Establish large-bore intravenous access and begin balanced crystalloid (e.g., lactated Ringer's) at 30 mL/kg ideal body weight for patients with hypotension or lactate > 2 mmol/L. Avoid 0.9% saline; hyperchloremic acidosis worsens acid-base derangement. Target a mean arterial pressure (MAP) ≥ 65 mm Hg. If vasopressors are required, norepinephrine is the first-line agent (starting dose 0.05-0.15 µg/kg/min, titrated to MAP ≥ 65 mm Hg). Vasopressin may be added as a second agent (0.03-0.04 units/min) to reduce norepinephrine dose. Do not use dopamine or phenylephrine as first-line agents; they provide no advantage and may worsen splanchnic vasoconstriction.

Step 2: Broad-Spectrum Antibiotics and Enteral Decolonization

Administer broad-spectrum intravenous antibiotics covering gram-negative rods and anaerobes: piperacillin-tazobactam 4.5 g IV every 6 hours, or a carbapenem (e.g., meropenem 1 g IV every 8 hours) in patients with β-lactam allergy or recent exposure. Initiate within the first hour of recognition. The WSES 2017 guideline recommends empiric therapy for transmural necrosis ^[10]A1c.

Additionally, in a prospective cohort study of 67 patients with AMI, oral antibiotics (non-absorbable, typically a combination of gentamicin, metronidazole , and vancomycin , though the exact regimen was not standardized) were independently associated with a decreased risk of intestinal necrosis (HR: 0.16; 95%; p = 0.01) ^[60]B2b. This approach, termed “intestinal topical antibiotic therapy,” should be considered when the patient is not undergoing immediate laparotomy and can tolerate oral/enteral administration.

Step 3: Early Full-Dose Anticoagulation

Initiate therapeutic anticoagulation as soon as the diagnosis of AMI is confirmed or strongly suspected, unless contraindicated by active bleeding or a planned emergency laparotomy. In an international study of 370 critically ill patients, early full-dose anticoagulation was associated with improved 30-day survival (53.5% vs 41.7%; p = 0.01; NNT = 8) ^[64]C4. The benefit persisted at 90 days (p = 0.02). The specific anticoagulant is not mandated by the trial; heparin (unfractionated or low-molecular-weight) is most commonly used. If unfractionated heparin is chosen, administer a bolus of 80 units/kg IV followed by an infusion of 18 units/kg/hour (target aPTT 1.5-2.5 times control). For LMWH, enoxaparin 1 mg/kg subcutaneously every 12 hours is a typical regimen. Monitor for bleeding: the trial noted a longer duration of mechanical ventilation in the anticoagulated group (p = 0.01), possibly reflecting increased transfusion requirements or closer monitoring ^[64]C4.

Step 4: Vasodilator Therapy for Non-Occlusive Mesenteric Ischemia (NOMI)

If NOMI is confirmed or strongly suspected (e.g., in a patient with low-flow states, use of vasopressors, or peritoneal dialysis), consider intra-arterial vasodilator therapy via a catheter placed in the superior mesenteric artery. A case series reported successful use of tolazoline 25 mg and glycerol trinitrate 200 µg as local vasodilators, though the procedure carried risks including cardiac arrest ^[62]C4. Papaverine (30-60 mg/h) is more commonly used in practice, but neither papaverine nor the tolazoline/nitrate combination is FDA-approved for this indication; use is off-label. Systemic vasodilators (e.g., intravenous nitroglycerin or sodium nitroprusside) are not recommended due to hypotension and lack of evidence.

Step 5: Monitoring and Transition to Operative Decision

Serial lactate measurements every 2-4 hours, arterial blood gas analysis, and abdominal examinations are essential. Worsening lactate, increasing abdominal pain, or peritonitis mandates immediate surgical consultation. If the patient stabilizes, proceed to definitive revascularization (endovascular or open) as discussed in the next section. The damage control approach, two-stage laparotomy with temporary abdominal closure and planned second-look, has been shown to reduce anastomotic dehiscence (5.3% vs 23.4%; p = 0.03) and need for ileostomy (2.6% vs 19.1%; p = 0.03) compared with one-stage resection in patients with limited AMI ^[59]B2b.

Drug Comparison Table

What NOT to Do

• Do not use dopamine or phenylephrine as first-line vasopressors; they may worsen splanchnic ischemia.
• Do not withhold anticoagulation for fear of bleeding unless there is active hemorrhage or immediate laparotomy planned.
• Do not use systemic vasodilators (IV NTG, SNP) for NOMI; they cause hypotension without proven benefit.

Pearl: Initiate broad-spectrum IV antibiotics, early full-dose anticoagulation (NNT=8), and oral non-absorbable antibiotics (if tolerated) within the first hour of suspecting AMI; these three interventions, combined with goal-directed resuscitation, form the medical bridge to definitive revascularization.

Resuscitation alone cannot salvage ischemic bowel; the decision to operate, and when, defines the trajectory of acute mesenteric ischemia. The first and most consequential surgical decision node is whether the disease warrants an operation at all, and if so how urgently. This choice rests on three axes: the presence of peritonitis, the viability of the bowel, and the time from symptom onset.

Indications for Operative Exploration

Absolute indications for emergency laparotomy include clinical peritonitis, pneumoperitoneum, or evidence of transmural necrosis on imaging (e.g., pneumatosis intestinalis, portal venous gas). The WSES guidelines emphasize that prompt diagnosis and intervention are essential to reduce mortality rates that exceed 50% ^[9]A1c. In the absence of peritonitis, a trial of endovascular revascularization may be considered, but the threshold for conversion to open surgery must be low.

Independent predictors of transmural bowel necrosis have been identified and should guide the decision to proceed directly to laparotomy ^[17]B2b:

Patients with two or more of these features have a high probability of transmural necrosis and should undergo immediate laparotomy without delay for further imaging or endovascular attempts.

Timing of Intervention

Time is the dominant modifiable risk factor. A recent study of 92 patients identified an inflection point at 48 hours from symptom onset (sensitivity 81%, specificity 63%) ^[34]B2b. Patients treated >48 hours after symptom onset had significantly higher rates of perioperative mortality (39% vs 14%) and short bowel syndrome (39% vs 12%; P =.002) compared with those treated within 48 hours ^[34]B2b. Revascularization beyond 48 hours was also associated with higher long-term mortality (HR 2.95), AMI recurrence (HR 6.36), and reintervention (HR 3.89) ^[34]B2b.

Significant predictors of perioperative mortality include age, time >48 hours, and lactate level at presentation ^[34]B2b. The WSES guidelines similarly stress that every hour of delay worsens outcome, and that a high index of suspicion must drive rapid CT angiography and surgical consultation ^{[9]A1c[10]A1c}.

>48 hours from symptom onset to revascularization is the single most actionable threshold, once crossed, the risk of death and short bowel syndrome more than doubles.

Choosing Between Endovascular and Open Revascularization

When revascularization is feasible, the choice between endovascular (EVR) and open surgical (OSR) approaches remains a central debate. A meta-analysis of 11 studies (1141 patients) found that EVR as the first strategy may not decrease short-term mortality compared with OSR (OR 0.79, 95%; very low certainty) ^[1]B2a. However, EVR was associated with decreased bowel resection (OR 0.42, 95%; P =.022) and short bowel syndrome (OR 0.39, 95%; P =.005) ^[1]B2a. The mortality benefit of EVR was not significantly impacted by thrombotic etiology, but was influenced by publication year ^[1]B2a.

Another meta-analysis of 39 studies (2369 patients) reported pooled mortality estimates of 40% for open surgery, 26% for endovascular therapy, and 32% for retrograde open mesenteric stenting, with overlapping confidence intervals, suggesting that the three approaches have similar mortality in the last 20 years ^[70]B2a.

A more recent comparative study of 92 patients found no difference between open and endovascular/retrograde open mesenteric stenting in long-term mortality, AMI recurrence, or reintervention ^[34]B2b.

Practical algorithm: For patients without peritonitis, with a short occlusion of the SMA amenable to aspiration or thrombolysis, and with rapid access to a skilled endovascular team, an initial endovascular approach is reasonable. For patients with peritonitis, extensive thrombosis, or failed endovascular attempts, open surgery remains the standard. The WSES guidelines endorse a personalized approach, noting that more than 20% of SMA emboli are associated with concurrent emboli to another arterial bed (spleen, kidney) which may influence the decision ^[9]A1c.

Damage Control and the Open Abdomen

For patients with extensive bowel ischemia, a damage control approach with planned second-look laparotomy is preferred. A prospective study of 85 patients comparing one-stage resection and anastomosis versus a two-stage damage control procedure found that the damage control group had significantly lower anastomotic dehiscence (5.3% vs 23.4%; P = 0.03) and need for ileostomy (2.6% vs 19.1%; P = 0.03) ^[59]B2b. The authors concluded that the damage control approach may represent a valid innovative option even in patients with limited acute mesenteric ischemia ^[59]B2b.

In a large NSQIP analysis of 5514 patients with mesenteric ischemia, the open abdomen was associated with increased mortality in patients who underwent resection alone (OR 1.58, 95% CI 1.38-1.81) but not in those who underwent revascularization (P = 0.528) ^[38]B2b. This suggests that the open abdomen is a useful tool when revascularization is performed, but should be avoided if possible in patients undergoing only resection. The open abdomen was also strongly associated with prolonged ventilator support >48 hours (OR 4.04, 95% CI 3.55-4.62) ^[38]B2b.

For non-occlusive mesenteric ischemia (NOMI), bedside laparoscopy in the ICU can avoid non-therapeutic laparotomy. In one series of 20 patients, non-therapeutic laparotomy was avoided in 9 patients, and mortality in that group was only 11% compared with in the resected group ^[37]B2b.

Pearl: The decision to operate is driven by predictors of transmural necrosis (arterial occlusion, acidosis, free fluid, combined thrombosis, leukocytosis) and the 48-hour time window, every hour lost beyond that threshold worsens survival and bowel salvage. Endovascular first is an option without peritonitis, but the surgeon must be ready to convert to open laparotomy or perform damage control second-look if bowel viability is uncertain.

Once the decision to operate is made, the surgeon must choose the optimal approach, revascularization technique, and perioperative strategy to maximize bowel salvage and survival. The evidence supports a tailored approach that balances the ischemic cause, the patient's physiologic reserve, and the degree of bowel necrosis.

Approach Selection: Open, Endovascular, or Hybrid

The choice between open surgical revascularization (OS) and endovascular therapy (EVT) depends on the presence of peritoneal signs, the anatomic level of occlusion, and institutional expertise. A large-scale analysis from the JROAD-DPC database (N = 2,211) found that in-hospital mortality (22.5% versus 21.4%, P = 0.72), bowel resection rates (8.2% versus 8.5%, P = 0.90), and major adverse cardiovascular events (11.6% versus 9.2%, P = 0.32) were comparable between EVT and OS in patients with acute superior mesenteric artery occlusion ^[80]B2b. Similarly, a population-based comparison found that the initial intervention, endovascular or surgical, was not an independent risk factor for in-hospital mortality ^[27]B2b.

A selective minimally invasive strategy, endovascular-first revascularization followed by laparoscopic second-look, has been reported with promising results. In a cohort of 42 patients, this approach yielded 30-day CIF-free survival of 71% (30/42) and short-term mortality of 11.9%; the 1-year primary patency rate was 90% ^[78]B2b. This strategy is best suited for patients without generalized peritonitis or hemodynamic instability.

• Open laparotomy is mandatory when peritoneal signs are present, when the patient is in shock, or when endovascular access fails. Open surgery allows direct bowel inspection, resection of necrotic bowel, and revascularization via embolectomy, bypass, or patch angioplasty.
• Endovascular-first is appropriate for patients with SMA embolism or thrombosis without peritonitis, especially when symptoms are <12 hours and the patient is hemodynamically stable.
• Hybrid approach (endovascular revascularization + open laparotomy) is often used when midgut viability is uncertain after catheter-directed therapy.

Revascularization Techniques and Conduit Choice

Revascularization should precede bowel resection whenever possible to limit the extent of ischemia. The goal is to restore pulsatile flow to the SMA and, if needed, the celiac axis.

• Open embolectomy via transverse arteriotomy is the standard for SMA embolism. The arteriotomy is closed primarily or with a vein patch.
• Bypass grafting from the infrarenal aorta or iliac artery to the SMA using autologous saphenous vein is preferred over prosthetic grafts because of the contaminated field often present in acute mesenteric ischemia. Prosthetic grafts are avoided when bowel necrosis or perforation is suspected.
• SMA reimplantation into the aorta is an option for proximal thrombosis.
• Local thrombolytic therapy (LTT) can be used for selected patients without peritoneal signs. In a small series, LTT achieved a mortality of 20% (1/5) in patients without peritoneal signs, but 62.5% (5/8) in those with peritonitis ^[73]C4.

Damage Control and the Staged Laparotomy Strategy

Damage control surgery (DCS) with a planned second-look laparotomy has become a cornerstone of management for patients with extensive ischemia or physiologic derangement. The WSES guidelines endorse the use of damage control techniques to allow reassessment of bowel viability before definitive anastomosis and abdominal closure ^[10]A1c.

A prospective study of 85 patients compared a two-step procedure (resection, temporary abdominal closure, second-look at 24-48 hours) with a one-step approach (single resection and anastomosis). The two-step group had significantly lower anastomotic dehiscence (5.3% versus 23.4%, P = 0.03) and need for ileostomy (2.6% versus 19.1%, P = 0.03) ^[59]B2b. At the second exploration, 21% (8/38) of patients in the two-step group required further resection due to progression of ischemia ^[59]B2b.

The open abdomen (OA) is frequently used in this context. Analysis of 5,514 cases in the NSQIP database showed that OA was associated with increased mortality (OR 1.58, 95% CI 1.38-1.81) and prolonged ventilator support >48 hours (OR 4.04, 95% CI 3.55-4.62) ^[38]B2b. However, among patients who underwent revascularization, this association disappeared (P = 0.528), suggesting that the open abdomen is a marker of severity rather than a cause of harm ^[38]B2b.

• Indications for OA: Massive bowel edema, need for second-look, abdominal compartment syndrome , or inability to achieve fascial closure.
• Temporary abdominal closure techniques include negative-pressure wound therapy (preferred) or a Bogota bag.

Second-Look Laparotomy

A planned second-look laparotomy is performed 24-48 hours after the initial operation to reassess bowel viability. It is mandatory when:

• Bowel viability is questionable after revascularization
• Extensive resection was performed
• The patient had a damage control procedure
• Colon ischemia is present (second-look rate 54% in patients with colon ischemia versus 25% without, P < 0.001) ^[75]C4

Bedside laparoscopy is a viable alternative in the ICU for patients with non-occlusive mesenteric ischemia (NOMI). In a case series, bedside laparoscopy avoided non-therapeutic laparotomy in 9/20 patients (45%), and mortality in that group was only 11% (1/9) ^[37]B2b.

Bowel Resection, Anastomosis, and Stoma Creation

Once irreversibly necrotic bowel is identified, it is resected. The extent of resection is guided by the demarcation between viable and non-viable bowel, which is often clearer after revascularization. Key principles:

• Primary anastomosis is generally avoided in the acute setting due to high leak rates (23.4% in one study) ^[59]B2b.
• Stoma creation is preferred when bowel viability is uncertain, when the patient is in shock, or when colon ischemia is present. In patients with AMI and concomitant colon ischemia, ostomy was associated with less repeated bowel resection (11% versus 63%, P = 0.001) and lower rate of short bowel syndrome (21% versus 79%, P < 0.001) compared with primary anastomosis ^[75]C4.
• Functional bowel length is critical: patients with <1 foot of residual bowel have very high mortality ^[77]B2b.

Perioperative Optimization Bundle

Perioperative care must be standardized to address the physiologic insults of ischemia-reperfusion, sepsis, and the surgical stress response. The following elements should be incorporated:

• Resuscitation with balanced crystalloids and blood products as needed; avoid lactated Ringer's if lactate is elevated (prefer Plasmalyte or similar).
• Early antimicrobial therapy covering enteric pathogens (gram-negative rods and anaerobes).
• Anticoagulation with unfractionated heparin is essential for patients with mesenteric venous thrombosis and should be initiated as soon as the diagnosis is confirmed, even preoperatively, unless there is active bleeding ^[74]B2a.
• Vasopressor minimization: Norepinephrine is preferred if needed, but alpha-agonists may worsen splanchnic vasoconstriction.
• Nutritional support: Early parenteral nutrition is indicated if bowel continuity is not restored; enteral nutrition can be cautiously introduced once bowel viability is confirmed.
• Multidisciplinary coordination: Involvement of vascular surgery, general surgery, interventional radiology, and critical care is essential for optimal outcomes.

Pearl: In patients with limited ischemia and no peritoneal signs, a selective minimally invasive approach (endovascular-first with laparoscopic second look) achieves 30-day CIF-free survival of 71% and short-term mortality of 11.9% ^[78]B2b.

Having weighed the operative approach, the surgeon must now anticipate the complications that follow. Acute mesenteric ischemia (AMI) carries a steep burden of both procedure-specific and disease-specific adverse events, graded by Clavien-Dindo, that drive monitoring, reintervention decisions, and informed consent.

Short Bowel Syndrome

Short bowel syndrome (SBS) is among the most consequential complications. In a meta-analysis of 1141 patients (11 studies), endovascular revascularization (EVR) as the first strategy was associated with a lower odds of SBS compared with open surgical revascularization (OSR) (OR 0.39, 95%;; very low certainty) ^[1]B2a. The same analysis found decreased bowel resection with EVR (OR 0.42, 95%; P =.022) ^[1]B2a. Delayed revascularization beyond 48 hours from symptom onset markedly increases the risk of SBS: patients treated >48 hours had a 39% incidence of SBS versus 12% for those treated within 48 hours ^[34]B2b. NNT for SBS prevention with early revascularization is not calculable from reported data ^[34]B2b.

Recurrent Ischemia and Reintervention

AMI recurrence and need for reintervention are more common with thrombotic etiology than embolic. In a cohort of 92 patients, acute thrombosis carried a HR of 5.97 for recurrence and HR of 8.02 for reintervention compared with embolic AMI ^[34]B2b. Revascularization >48 hours after symptom onset was also associated with higher long-term AMI recurrence (HR 6.36) and reintervention (HR 3.89) ^[34]B2b. No difference in recurrence or reintervention was observed between open and endovascular/retrograde open mesenteric stenting revascularization (and, respectively) ^[34]B2b. In a series of 65 patients treated with retrograde open mesenteric stenting, the estimated freedom from stent-related reintervention at three years was 68.2% (95% CI 50%-81%) ^[35]B2b.

Mortality and Morbidity

Thirty-day postoperative mortality after bowel resection for AMI is 27.9%, with morbidity 56.6% (N = 861, median age 69 years) ^[30]B2b. In-hospital mortality for AMI requiring revascularization ranges from 31% to 48% ^{[35]B2b[16]B2b}. The strongest independent predictors of perioperative mortality include age, time from symptom onset to revascularization >48 hours, and lactate level at presentation ^[34]B2b. Among patients undergoing damage control surgery (DCS), mortality rises with the number of DCS criteria: 24% with one criterion, 48% with two, and 62% with three or more ^[16]B2b. Independent predictors of mortality in DCS are age (P =.018) and INR ≥ 1.7 (P =.001) ^[16]B2b.

Open Abdomen and Ventilator Dependence

The open abdomen (OA) is a frequent sequel of DCS for AMI. Among 5514 cases (83.9% resection, 7% revascularization), OA was associated with an OR of 1.58 for mortality (95% CI 1.38-1.81; P < 0.001) after adjustment for demographics, transfer status, comorbidities, and operative time ^[38]B2b. However, among patients who underwent revascularization, no such association was seen (P = 0.528) ^[38]B2b. OA also strongly predicted ventilator support >48 hours (OR 4.04, 95% CI 3.55-4.62; P < 0.001) ^[38]B2b.

Other Complications

• Non-occlusive mesenteric ischemia: NOMI, often triggered by low-flow states, carries a mortality of 50-69% ^[37]B2b. Bedside laparoscopy in the ICU may aid diagnosis ^[37]B2b.

Pearl: Time to revascularization >48 hours, thrombotic etiology, and elevated lactate at presentation independently predict perioperative mortality, recurrence, and short bowel syndrome; early revascularization (<48 hours) is the most modifiable factor to reduce these complications ^[34]B2b.

Despite advances in managing complications, the mortality of acute mesenteric ischemia (AMI) has remained substantial, but the trajectory of treatment has shifted dramatically over the past five decades. The evolution from a nearly uniformly fatal condition to one with improving survival reflects earlier diagnosis, subtype-specific revascularization, and a move away from resection-only approaches.

The Era of Late Diagnosis and High Mortality (pre-1980s)

Before the 1980s, AMI was diagnosed late, often at laparotomy after bowel infarction had already occurred. Krausz and Manny reported an overall mortality of 77.5% (31 of 40 patients) in 1978, emphasizing that only a high index of suspicion and aggressive early operation could improve outcomes ^[94]C4. Collated historical series from that era showed survival rates ranging from 0% to 40% ^[90]B2b. The standard of care was exploratory laparotomy with bowel resection; revascularization was rarely attempted and angiography was used inconsistently.

The Shift to Revascularization (1980s-2000s)

Recognition that arterial occlusion, not bowel necrosis per se, was the primary driver of mortality led to a paradigm shift toward revascularization. Johnston et al. (1995) reported that mesenteric bypass grafts for acute thrombosis achieved an early mortality of 22% (2 deaths from ongoing bowel ischemia) and a cumulative survival of 78% at 1 month and 65% at 1 year ^[95]C4. Endean et al. (2001) demonstrated that survival varied dramatically by subtype: 87% for mesenteric venous thrombosis versus 41% for arterial embolism and 38% for arterial thrombosis ^[90]B2b. Their overall survival of 52% compared favorably with the historical 25%, confirming that revascularization plus resection improved outcomes ^[90]B2b. During this period, open surgical embolectomy and bypass became standard for acute SMA occlusion, while venous thrombosis was managed with anticoagulation and selective surgery.

The Endovascular Revolution (2000s-present)

The 21st century brought endovascular techniques, percutaneous transluminal angioplasty with stenting, catheter-directed thrombolysis, and aspiration thrombectomy, that reduced the need for laparotomy in selected patients. Gries et al. (2024) reviewed modern revascularization strategies, noting that endovascular-first approaches are increasingly favored for SMA embolism and thrombosis when no bowel necrosis is present ^[96]D5. Acosta-Mérida et al. (2020) documented a significant decrease in angiography use over time (p = 0.004) and a corresponding increase in CT utilization (p < 0.001), reflecting the shift from diagnostic angiography to CT angiography as the primary imaging modality ^[92]B2b. The ACR Appropriateness Criteria now endorse CT angiography as the first-line imaging test for suspected AMI ^[88]A1c, and radiologic management (including endovascular revascularization) is recommended when feasible ^[89]A1c.

Changing Patient Demographics and Risk Factors

Over the same period, the patient population has evolved. Acosta-Mérida et al. observed a significant increasing linear trend in Charlson comorbidity scores (p = 0.008), antiplatelet drug use (p < 0.001), and arterial thrombosis as the causative subtype (p < 0.001) ^[92]B2b. Digoxin use, once common in elderly patients with atrial fibrillation , decreased significantly (p < 0.001) ^[92]B2b. A meta-analysis of 20 studies (5011 patients) identified older age, arterial occlusive etiology (vs. venous thrombosis), heart failure, renal disorders, and peripheral vascular disease as preoperative risk factors for short-term postoperative mortality ^[91]B2a. Among critically ill ventilated patients with shock, norepinephrine use (OR 3.5), epinephrine use (OR 2.0), and serum lactate >3 mmol/L (OR 2.9) were independently associated with AMI after cardiac surgery ^[98]B3b.

Abandoned Practices and Lessons Learned

Several historical practices have been abandoned or relegated to niche roles. Routine diagnostic angiography for suspected AMI has been replaced by CT angiography, which is noninvasive and widely available ^[92]B2b. Digoxin, once used for rate control in atrial fibrillation , is now avoided because of its splanchnic vasoconstrictive effects ^[92]B2b. Non-therapeutic laparotomy, once common when clinical suspicion was high but imaging was equivocal, can now be reduced by bedside laparoscopy in the ICU, which avoided non-therapeutic laparotomy in 9 of 20 patients with non-occlusive mesenteric ischemia and reduced mortality in that subgroup to 11% ^[37]B2b.

Current Paradigm and Future Directions

Today's standard of care integrates early clinical suspicion (sudden-onset and/or morphine -requiring abdominal pain, present in 88% of AMI patients ^[12]B3b), prompt CT angiography, subtype-specific revascularization (endovascular or open), and damage-control surgery when bowel necrosis is present. Mortality remains high, up to 50% overall ^[23]D5, but has improved from the 77-80% rates of the 1970s. Acute lung injury complicates nearly 30% of AMI cases and is a major contributor to mortality ^[23]D5. Future advances will likely focus on biomarkers for earlier diagnosis, refined endovascular techniques, and strategies to mitigate ischemia-reperfusion injury. These trends set the stage for the prognosis and natural history discussed in the next section.

Pearl: The single most important historical lesson is that delay in diagnosis is the primary driver of mortality; the evolution of treatment is fundamentally a story of earlier recognition and faster revascularization, which has reduced mortality from ~80% to ~40-50% over five decades.

Treatment advances have not fundamentally altered the grim outlook of acute mesenteric ischemia. Mortality remains the dominant endpoint, and the disease trajectory is determined largely by etiology, the interval to intervention, and the severity of physiologic derangement at presentation.

In-Hospital and Short-Term Mortality

Hospital mortality in contemporary population-based studies is 64%, with 1-year all-cause mortality reaching 74% ^[2]B2b. Even among patients who receive active treatment, surgery, endovascular therapy, or both, the in-hospital mortality is 32% and 1-year mortality is 51% ^[2]B2b. Single-center series report comparable figures: in-hospital mortality 41.2%, 30-day mortality 46.5% ^[6]B2b. The World Society of Emergency Surgery guidelines consistently cite mortality rates exceeding 50% ^{[9]A1c[10]A1c}. A national survey of Spanish surgeons placed in-hospital mortality above 50% ^[43]C4. The RADIAL score validation study of 693 patients reported overall mortality 62.4% and derived three risk strata: low (30-40%), intermediate (50-60%), and high (80%) ^[102]B2b. The CALLY index demonstrated only modest discrimination for 30-day mortality (AUC 0.64) in a separate cohort ^[101]B2b.

Mortality after laparotomy is heavily influenced by the extent of intestinal compromise. In 861 patients undergoing bowel resection for AMI, 30-day postoperative morbidity was 56.6% and mortality was 27.9% ^[30]B2b. Patients treated with damage control surgery have a stepwise increase in mortality according to the number of DCS criteria: 24% with one criterion, 48% with two, and 62% with three or more ^[16]B2b.

The 48-Hour Inflection Point

Time from symptom onset to revascularization is the single most actionable prognostic variable. A landmark analysis of 92 patients identified a clear inflection point at 48 hours (sensitivity 81%, specificity 63%). Patients revascularized after 48 hours had significantly higher perioperative mortality (39% vs 14%) and short bowel syndrome (39% vs 12%; P =.002) ^[34]B2b. Delayed revascularization also increased long-term mortality (HR 2.95), AMI recurrence (HR 6.36), and reintervention (HR 3.89) ^[34]B2b. Independent predictors of perioperative mortality included age, lactate level at presentation, and revascularization >48 hours ^[34]B2b.

Etiology-Specific Prognosis

Arterial occlusive AMI accounts for 57.8% of cases, followed by NOMI (22.5%), mechanical/secondary ischemia (14.7%), and venous AMI (4.9%) ^[6]B2b. Compared with embolic AMI, acute SMA thrombosis carries an increased risk of recurrence (HR 5.97) and need for reintervention (HR 8.02), but no difference in long-term mortality (HR 0.79) ^[34]B2b.

Radiographic Prognosticators

Pneumatosis intestinalis and portal venous gas have historically been associated with 70% mortality, leading many surgeons to proceed directly to laparotomy. A systematic review of 308 patients updated this estimate to 31% overall mortality, 69% among those with confirmed ischemia versus 14% among those without ischemia ^[42]B2a. These findings mandate clinical correlation: pneumatosis and portal venous gas alone do not commit a patient to resection. In NOMI, no single CT finding (defect of mural enhancement, pneumatosis, portal gas, bowel wall thinning) predicted survival; however, a shorter interval from CT to vasodilator infusion was associated with better survival (median 187.5 vs 310 minutes; P = 0.048) ^[40]B2b.

Natural History of Untreated and Non-Operatively Managed Disease

The small intestine can compensate for a 75% reduction in mesenteric blood flow for up to 12 hours ^[10]A1c. Beyond that, irreversible transmural necrosis develops rapidly. More than 20% of SMA emboli are associated with concurrent emboli to other arterial beds (spleen, kidney) ^[9]A1c. Non-occlusive mesenteric ischemia may progress silently, especially in critically ill patients; delayed recognition is common. In a cohort of NOMI patients, those without peritoneal signs treated with local thrombolytic therapy had 20% mortality, compared with 62.5% in those who already had signs of peritonitis ^[73]C4. Portal venous gas and pneumatosis in the setting of confirmed ischemia carried a 69% mortality ^[42]B2a, reinforcing the need for swift decision-making.

Long-Term Outcomes and Recurrence

Late mortality in AMI remains substantial. Cumulative survival risk at 3 years after retrograde open mesenteric stenting was 59.7% ^[35]B2b. In a separate surgical cohort, the mean survival was, but dropped to 9.5 months for patients over 70 years (P = 0.035) ^[100]C4. Freedom from stent-related reintervention at 3 years was 68.2% ^[35]B2b. Acute thrombosis subtype independently predicted recurrence and reintervention ^[34]B2b. Endovascular and open approaches showed equivalent long-term mortality and recurrence rates after adjustment for baseline severity ^{[34]B2b[35]B2b[68]B2b}.

Pearl: Time from symptom onset to revascularization is the most modifiable prognostic factor; treating within 48 hours reduces perioperative mortality from 39% to 14% and short bowel syndrome from 39% to 12%, every hour counts.

Following the prognostic patterns outlined above, the course of acute mesenteric ischemia is substantially altered by age, pregnancy, and immune status, each modifying the diagnostic threshold, the operative calculus, and the expected outcome.

Elderly

The typical patient with acute mesenteric ischemia is elderly: the median age in a population-based study was 79 years (range 32-104), with 57% female ^[2]B2b. Age is an independent predictor of perioperative mortality (, ^[34]B2b; also univariate P = 0.01, ^[28]B2b). The median age of patients undergoing bowel resection is 69 years ^[30]B2b.

Presentation may be blunted by diminished pain perception, coexisting dementia, or polypharmacy. The comorbidity burden (Charlson index) has increased over time ^[92]B2b, and the prevalence of digoxin use has declined ^[92]B2b, a welcome change, as digoxin was a univariate risk factor for mortality ^[28]B2b.

• Operative decisions: Damage control surgery (DCS) is often employed. The open abdomen, in the overall cohort, was associated with increased mortality (OR 1.58, 95% CI 1.38-1.81, P < 0.001) but not after revascularization (P = 0.528) ^[38]B2b. DCS criteria (age, INR ≥ 1.7) are independent predictors of mortality ^[16]B2b.
• Prognosis: Overall hospital mortality 64%, and 1‑year mortality 74% ^[2]B2b. Among those receiving active treatment, in-hospital mortality was 32% and 1‑year mortality 51% ^[2]B2b.

Pediatrics

Acute mesenteric ischemia in children is exceedingly rare; the adult incidence of 8.7/100 000 ^[2]B2b is not generalizable. Non-occlusive mesenteric ischemia (NOMI) is a recognized cause, particularly in the setting of severe infection. A case report describes intestinal necrosis due to NOMI in a child with Mycoplasma pneumoniae pneumonia ^[32]C4.

• Presentation: Abdominal pain, distension, and feeding intolerance are non-specific, leading to frequent delay. A high index of suspicion is required in children with sepsis, congenital heart disease, or vasculitis.
• Diagnosis: CT with intravenous contrast is the reference standard, but radiation exposure is a concern. Consider ultrasound or MRI as initial screening if the child is stable and suspicion is low; do not delay CT in a deteriorating patient.
• Management : Follows the same principles of revascularization and resection as in adults. Preserving bowel length is critical for growth; therefore, a low threshold for a second-look laparotomy is recommended. There are no age-adjusted dose data for vasodilators or anticoagulants from the provided evidence.

Pregnancy

No data from the provided references address pregnancy. The following is based on clinical consensus. The hypercoagulable state of pregnancy increases the risk of mesenteric venous thrombosis, a rare cause of acute mesenteric ischemia.

• Presentation: Abdominal pain, nausea, vomiting are easily attributed to pregnancy; severe, out-of-proportion pain should raise suspicion.
• Diagnosis: CT with intravenous contrast is the gold standard, but fetal radiation exposure is a concern. Discuss with the radiologist: MRI/MRA may be an alternative if time permits, but in a life-threatening situation, CT should not be withheld.
• Treatment: Laparotomy and revascularization as indicated. For mesenteric venous thrombosis, anticoagulation with unfractionated or low-molecular-weight heparin is safe in pregnancy (no teratogenic risk). Warfarin is contraindicated due to fetal hemorrhage. Postoperative fetal monitoring is essential. If the fetus is viable, cesarean delivery before laparotomy should be considered.
• Breastfeeding : Heparin is safe; warfarin is also safe during breastfeeding. No data on direct oral anticoagulants.

Immunocompromised

No specific data from the provided references. Patients on immunosuppressive therapy (transplant recipients, chemotherapy, chronic corticosteroids, HIV/AIDS) may have an atypical presentation due to diminished inflammatory response. Abdominal pain may be absent or minimal; sepsis may be the first sign. A low threshold for early CT imaging is paramount. Management follows the same surgical principles, but perioperative risks (infection, impaired wound healing) are higher, and a lower threshold for damage control is warranted.

Pearl: In pregnancy, CT should not be delayed for life-threatening ischemia; heparin is the anticoagulant of choice for mesenteric venous thrombosis.

Having addressed the unique challenges of AMI in special populations, clinicians must shift focus to prevention of the index event and surveillance for recurrence. No population-based screening for acute mesenteric ischemia (AMI) is endorsed by any major guideline; however, secondary prevention and close post-revascularization surveillance are critical given the high rates of recurrence and reintervention.

Primary Prevention

Primary prevention targets the underlying risk factors for each AMI etiology:

• SMA embolism: Anticoagulation for atrial fibrillation (AF) reduces embolic stroke, but no trial specifically reports AMI reduction; extrapolation from AF guidelines recommends long-term anticoagulation for CHA₂DS₂-VASc ≥2 in men or ≥3 in women.
• SMA thrombosis: Aggressive atherosclerotic risk factor control, smoking cessation, hypertension management , statin therapy, and diabetes control, is standard, though no RCT has studied AMI as an endpoint.
• Mesenteric venous thrombosis (MVT): Prompt diagnosis and treatment of hypercoagulable states (e.g., factor V Leiden, prothrombin mutation, JAK2 in myeloproliferative neoplasms) and avoidance of estrogen-containing medications in high-risk patients ^[104]D5.
• Non‑occlusive mesenteric ischemia (NOMI): Maintain adequate splanchnic perfusion during critical illness, avoid low-output states and excessive vasopressor doses; early goal-directed therapy for sepsis.

Secondary Prevention (Preventing Recurrence)

After surviving an index AMI episode, the risk of recurrence is substantial: in a 2025 series, AMI secondary to acute thrombosis carried a HR 5.97 (95% CI 1.05‑25.38) for recurrence and HR 8.02 (95% CI 1.04‑61.95) for reintervention compared with embolic AMI ^[34]B2b. Revascularization >48 hours after symptom onset was independently associated with higher long-term mortality (HR 2.95), recurrence (HR 6.36), and reintervention (HR 3.89) ^[34]B2b.

• Anticoagulation: Patients with embolic AMI should receive lifelong anticoagulation ( warfarin or direct oral anticoagulant) unless contraindicated; for MVT, anticoagulation is continued for ≥3-6 months and indefinitely in provoked or recurrent cases ^[104]D5.
• Anti‑thrombotic therapy: Following mesenteric stenting or bypass, dual antiplatelet therapy ( aspirin + clopidogrel for 1-3 months) is commonly used, followed by single-agent aspirin, despite the absence of randomized data in mesenteric vessels.
• Risk factor modification: Diabetes (OR 2.77, 95% CI 1.37‑5.61) and sepsis at presentation (OR 2.32, 95% CI 1.18‑4.58) independently predicted 30‑day major adverse events ^[66]C4; tight glycemic control and prompt infection management are logical but unproven for recurrence prevention.

Surveillance After Revascularization

Surveillance imaging is recommended to detect restenosis before symptom recurrence:

• Duplex ultrasound at 6 months and 12 months post-procedure, then annually; a peak systolic velocity >275-300 cm/s in the SMA suggests significant stenosis.
• CTA (computed tomography angiography) if duplex is technically inadequate or if symptoms recur; magnetic resonance angiography can be substituted for patients with renal impairment.

Among patients treated for chronic mesenteric ischemia (CMI), nearly 40% developed in‑stent restenosis, and 50% required reintervention by 2 years ^[110]C4. Freedom from restenosis and reintervention at 2 years was only 60% ± 10% and 50% ± 10%, respectively ^[110]C4. Similar rates occur in AMI survivors: by 2 years, freedom from symptom recurrence was 72% ± 8% and freedom from reinterventions 74% ± 8% in a multicenter series ^[106]C4.

Table 1: Surveillance Intervals After Mesenteric Revascularization

Patient Education

Educate survivors and their families:

• Recognize early symptoms: Sudden severe abdominal pain out of proportion to exam warrants immediate emergency evaluation.
• Medication adherence: Consistent use of antiplatelet/anticoagulant medications is essential; never stop without consulting the vascular team.
• Smoking cessation: Active tobacco use is a potent risk factor, referral to a cessation program is mandatory.
• Dietary counseling: For patients with short bowel after extensive resection, specialized nutritional support (including parenteral nutrition if needed) prevents malnutrition and dehydration.

Pearl: The single most modifiable predictor of AMI recurrence and reintervention is revascularization within 48 hours of symptom onset ^[34]B2b; combined with lifelong anti‑thrombotic therapy, aggressive risk factor control, and regular duplex surveillance, the 2‑year reintervention rate can be minimized from the 50% range ^[110]C4 to a lower trajectory.